Laboratory Monitoring for Testosterone Therapy
For patients on testosterone therapy, draw testosterone levels, hematocrit, and PSA (in men ≥40 years) at baseline, at 3-6 months after initiation, and then annually thereafter. 1
Baseline Laboratory Testing
Before initiating testosterone therapy, obtain:
- Testosterone level (total testosterone, ideally two fasting morning samples to confirm diagnosis)
- Hematocrit or hemoglobin (baseline hematocrit >50% is a relative contraindication) 1
- PSA and digital rectal examination (in men ≥40 years, particularly those with baseline PSA >0.6 ng/ml) 1
The FDA label for injectable testosterone confirms the need for hemoglobin and hematocrit monitoring to detect polycythemia 2.
Follow-Up Monitoring Schedule
At 3-6 Months After Initiation:
Testosterone level - timing depends on formulation:
Hematocrit - stop therapy if hematocrit >54% until it decreases to a safe level; evaluate for hypoxia and sleep apnea before reinitiating at reduced dose 1
PSA (in men ≥40 years with baseline PSA >0.6 ng/ml) 1
Annual Monitoring (After First Year):
- Testosterone level - ensure maintenance in mid-normal range
- Hematocrit - continue annual monitoring for polycythemia 1
- PSA and digital rectal examination - follow age-appropriate prostate cancer screening guidelines 1
Critical Safety Thresholds Requiring Action
Obtain urological consultation if:
- PSA increases >1.4 ng/ml within any 12-month period 1
- PSA velocity >0.4 ng/ml/year (using 6-month level as reference, applicable if >2 years of data) 1
- Abnormality detected on digital rectal examination 1
- AUA/IPSS prostate symptom score >19 1
Stop testosterone therapy if:
- Hematocrit >54% 1
Additional Considerations
The 2010 Endocrine Society guidelines 1 represent the most comprehensive monitoring framework and supersede the 2006 version 4, though both are consistent in their core recommendations. The key difference is the 2010 guideline specifies PSA monitoring primarily for men ≥40 years with baseline PSA >0.6 ng/ml, providing more nuanced guidance.
Common pitfall: Measuring testosterone at the wrong time relative to injection timing can yield misleading results. For injectable formulations, always measure midway between injections to assess steady-state levels 1. Document the timing of last injection and blood draw for proper interpretation 5.
Bone mineral density should be measured after 1-2 years only in hypogonadal men with osteoporosis or low-trauma fracture 1.
Serum cholesterol may increase during therapy and should be monitored as clinically indicated 2. In diabetic patients, testosterone may decrease blood glucose, potentially requiring insulin adjustment 2.